AI MARKET SCANNING

Biomea Fusion, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.03%
MAX GAP RECORD -7.32%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BMEA
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
-0.79%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
+0.64%
Mar 24, 2026 Earnings Release 2026-03-24 (AFTER CLOSE)
+0.89%
Nov 04, 2025 Earnings Release 2025-11-04 (AFTER CLOSE)
-0.79%
Aug 05, 2025 Earnings Release 2025-08-05 (AFTER CLOSE)
+1.90%
May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE)
+1.80%
Oct 29, 2024 Earnings Release 2024-10-29 (AFTER CLOSE)
+1.00%
Jul 31, 2024 Earnings Release 2024-07-31 (AFTER CLOSE)
+6.64%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.5%
Bullish Gaps (5)
Bearish Gaps (1)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BMEA

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗